Holen Sie sich die Stockscreener-App
8.92
1.83%
0.16
Handel nachbörslich:
9.10
0.18
+2.02%
Schlusskurs vom Vortag:
$8.76
Offen:
$8.7
24-Stunden-Volumen:
357.36K
Relative Volume:
0.78
Marktkapitalisierung:
$440.85M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.4114
EPS:
-6.32
Netto-Cashflow:
$-194.72M
1W Leistung:
-1.55%
1M Leistung:
-8.23%
6M Leistung:
-47.00%
1J Leistung:
-41.81%
1-Tages-Spanne:
$8.58
$8.97
1-Wochen-Bereich:
$8.535
$9.27
52-Wochen-Spanne:
$8.535
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Regenxbio Inc Holdin - GuruFocus.com
Sorrento Therapeutics (OTCMKTS:SRNEQ) & REGENXBIO (NASDAQ:RGNX) Financial Survey - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan
When (RGNX) Moves Investors should Listen - Stock Traders Daily
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - StockTitan
Assenagon Asset Management S.A. Lowers Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $9.1 amid market challenges By Investing.com - Investing.com South Africa
RGNX stock touches 52-week low at $9.1 amid market challenges - Investing.com
SG Americas Securities LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
How the (RGNX) price action is used to our Advantage - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Chardan Capital - Defense World
The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - MarketBeat
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - Citizentribune
REGENXBIO (NASDAQ:RGNX) Trading Down 6.4%Time to Sell? - MarketBeat
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 - Citizentribune
ABBV-RGX-314 shows promise in wet AMD treatment By Investing.com - Investing.com UK
JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc - Yahoo Finance
Investors in REGENXBIO (NASDAQ:RGNX) from five years ago are still down 72%, even after 16% gain this past week - Simply Wall St
REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.6%Should You Buy? - MarketBeat
Regenxbio Inc [RGNX] Insider Activity: An Update for Investors - Knox Daily
Millennium Management LLC Has $3.59 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
(RGNX) On The My Stocks Page - Stock Traders Daily
Raymond James resumes coverage on Regenxbio stock with Outperform rating - Investing.com India
What 4 Analyst Ratings Have To Say About Regenxbio - Benzinga
REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Raymond James - MarketBeat
RGNX stock touches 52-week low at $9.28 amid market challenges By Investing.com - Investing.com South Africa
RGNX stock touches 52-week low at $9.28 amid market challenges - Investing.com
REGENXBIO releases new data on DMD drug ahead of earnings - MSN
Dimensional Fund Advisors LP Has $12.96 Million Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Squarepoint Ops LLC - MarketBeat
Selling Buzz: Regenxbio Inc [RGNX] Director KARABELAS ARGERIS N sells 10,000 shares of the company - Knox Daily
A Tale of Resilience: Regenxbio Inc Amid Stock Market Turbulence - The InvestChronicle
Regenxbio director Karabelas sells $101,052 in stock By Investing.com - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas Sells 10,000 Shares - Defense World
Learn to Evaluate (RGNX) using the Charts - Stock Traders Daily
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference - cnhinews.com
Recent Insider Activity Could Benefit Regenxbio Inc (RGNX) - Knox Daily
Can you still get a good price for Regenxbio Inc (RGNX) Shares at this point? - US Post News
Stock Surge: Regenxbio Inc (RGNX) Closes at 10.49, Marking a -2.87 Increase/Decrease - The Dwinnex
Cubist Systematic Strategies LLC Buys 79,655 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $10.48 amid market challenges - Investing.com Australia
RGNX stock touches 52-week low at $10.48 amid market challenges By Investing.com - Investing.com South Africa
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A company insider recently sold 10,000 shares of Regenxbio Inc [RGNX]. Should You Sale? - Knox Daily
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regenxbio Inc-Aktie (RGNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):